Hypertension-induced organ damage in African americans: Transforming growth factor-β1 excess as a mechanism for increased prevalence

Current Hypertension Reports

Volumn 2, Issue 2, 2000, Pages 184-191

  August, Phyllis ^a   Leventhal, Beth ^a   Suthanthiran, Manikkam ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

BLOOD; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; ETHNOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; NEGRO; PHYSIOLOGY; PREVALENCE; REVIEW; STATISTICAL MODEL;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; PREVALENCE; RECEPTORS, ANGIOTENSIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 0034166728     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0080-5     Document Type: Article

References (61)

1. Burt Vl, Whelton P, Rocella EJ, et al.: Prevalence of hypertension in the US adult population: results of the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25: 305-313.
2. The Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure. The sixth report. Arch Intern Med 1997, 157: 2413-2446.
3. Lackland DT, Keil JE: Epidemiology of hypertension in African Americans. Semin Nephrol 1996, 16: 63-70.
4. Flack JM, Staffileno BA: Hypertension in blacks. In Hypertension: A Companion to Brenner and Rector's The Kidney. Edited by Oparil S, Weber MA. Philadelphia: WB Saunders; 2000: 558-563.
5. He J, Whelton PK: What is the role of dietary sodium and potassium in hypertension and target organ injury? Am J Med Sci 1999, 317: 152-159.
6. Ambrosius WT, Bloem LJ, Zhou L, et al.: Genetic variants in the epithelial sodium channel in relation to aldosterone and potassium excretion and risk for hypertension. Hypertension 1999, 34: 631-637.
7. Dong Y, Zhu H, Sagnella GA, et al.: Association between the C825T polymorphism of the G protein beta3-subunit gene and hypertension in blacks. Hypertension 1999, 34: 1193-1196.
8. Taylor JO, Borhani NO, Entwisle G: Summary of the baseline characteristics of the hypertensive participants. Hypertension 1983, 5 [suppl 4]: 44-50.
9. Rosamond WD, Folsom AR, Chambless LE, et al.: Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999, 30: 736-740.
10. U. S. Renal Data System (USRDS) 1998 Annual Data Report. Bethesda: The National Institutes of Health & NIDDK; 1998.
11. Klag MJ, Whelton PK, Randall BL, et al.: End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA 1997, 277: 1293-1298.
12. Klahr S: Prevention of progression of nephropathy. Nephrol Dial Transplant 1997, 12(suppl 2):63-66.
13. Dooley MA, Hogan S, Jennette C, Falk R: Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997, 51: 1188-1195.
14. Rostand SG, Brown G, Kirk KA, et al.: Renal insufficiency in treated essential hypertension. N Engl J Med 1989, 320: 684-688.
15. Perry HM Jr, Miller JP, Fornoff JR, et al.: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995, 25: 587-594.
16. Freedman BI, Soucie JM, McClellan WM: Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 1997, 8: 1942-1945.
17. Bergman S, Key BO, Kirk KA, et al.: Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. Am J Kidney Dis 1996, 27: 341-346.
18. Roberts AM, Sporn MB: Transforming growth factor. Adv Cancer Res 1988, 51: 107-145.
19. Massagne J: The transforming growth factor family. Ann Rev Cell Dev Biol 1990, 6: 597-641.
20. Vilarreal FJ, Dillman WH: Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta, fibronectin and collagen. Am J Physiol 1992, 262: H1861-H1866.
21. Sarzani R, Brecher P, Chobanian AV: Growth factor expression in aorta of normotensive and hypertensive rats. J Clin Invest 1989, 83: 1404-1408.
22. Ketteler M, Noble NA, Border WA: Increased expression of transforming growth factor beta in renal disease. Curr Opin Nephrol Hypertens 1994, 3: 446-452.
23. Border WA, Noble NA: Interactions of transforming growth factor and angiotensin II in renal fibrosis. Hypertension 1998, 31: 181-188.
24. Isaka Y, Fujiwara Y, Ueda N, et al.: Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J Clin Invest 1993, 92: 2597-2601.
25. Akagi Y, Isaka Y, Arai M, et al.: Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996, 50: 148-155.
26. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996, 45: 522-530.
27. Bottinger EP, Letterio JJ, Roberts AB: Biology of TGF-beta 1 in knockout and transgenic mouse models. Kidney Int 1997, 51: 1255-1360.
28. Yamamoto T, Noble NA, Cohen AH, et al.: Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996, 49: 461-469.
29. Iwano M, Kubo A, Nishino T, et al.: Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int 1996, 49: 1120-1126.
30. 1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 1996, 49: 1297-1303.
31. Suthanthiran M, Khanna A, Cukran D, et al.: Transforming growth factor B1 hyperexpression in African American endstage renal disease patients. Kidney Int 1998, 53: 639-644.
32. Li B, Khanna A, Sharma V, et al.: TGF-, 1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999, 33: 271-275.
33. 1 Hyperexpression in African American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci U S A 2000, in press.
34. Ergul S, Parish DC, Puett D, Ergul A: Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 1996, 28: 652-655.
35. Kurihara H, Yoshizumi M, Sugiyama T, et al.: Transforming growth factor β stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989, 159: 1435-1440.
36. Antonipillai I, Hoang Le T, Soceneantu L, Horton R: Transforming growth factor is a renin secretagogue at picomolar concentrations. Am J Physiol 1993, 265: F537-F541.
37. Nabel EG, Shum L, Pompili VJ, et al.: Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A 1993, 90: 10759-10763.
38. Saltis J, Agrotis A, Bobil A: Regulation and interactions of transforming growth factor-beta with cardiovascular cells: implications for development and disease. Clin Exp Pharmacol Physiol 1996, 23: 193-200.
39. Agrotis A, Saltis J, Bobik A: Effect of transforming growth factor beta 1 on platelet-derived growth factor receptor binding and gene expression in vascular smooth muscle cells from SHR and WKY rats. Clin Exp Pharmacol Physiol 1994, 21: 145-148.
40. Cambien F, Ricard S, Troesch A, et al.: Polymorphisms of the transforming growth factor-beta 1 gene in relation to myocardial infarction and blood pressure. The Etude Cas-Temoin de l'Infarctus du Myocarde (ECTIM) Study. Hypertension 1996, 28: 881-887.
41. 1 production, fibrotic lung disease and graft fibrosis after lung transplantation. Transplantation 1998, 66: 1014-1020.
42. Chapman JN, Mayet J, Chang CL, et al.: Ethnic differences in the identification of left ventricular hypertrophy in the hypertensive patient. Am J Hypertens 1999, 12: 437-442.
43. Olutade BO, Gbadebo TD, Porter VD, et al.: Racial differences in ambulatory blood pressure and echocardiographic left ventricular geometry. Am J Med Sci 1998, 315: 101-109.
44. Arnett DK, Rautaharju P, Crow R, et al.: Black-white differences in electrocardiographic left ventricular mass and its association with blood pressure (the Atherosclerosis Risk in Communities study). Am J Cardiol 1994, 74: 247-252.
45. Flack JM, Gardin JM, Yunis C, Liu K: Static and pulsatile blood pressure correlates of left ventricular structure and function in black and white young adults: The CARDIA study. Am Heart J 1999, 138: 856-864.
46. Mayet J, Chapman M, Li CK, et al.: Ethnic differences in the hypertensive heart and 24-hour blood pressure profile. Hypertension 1998, 31: 1190-1194.
47. Porreca E, Di Febbo C, Mincione G, et al.: Increased transforming growth factor-β production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997, 30: 134-139.
48. Williams JE, Massing M, Rosamond WD: Racial disparities in CHD mortality from 1968-1992 in the state economic areas surrounding the ARIC study communities. Atherosclerosis Risk in Communities. Ann Epidemiol 1999, 9: 472-480.
49. Barnett E, Armstrong DL, Casper ML. Evidence of increasing coronary heart disease mortality among black men of lower social class. Ann Epidemiol 1999, 9: 464-471.
50. Taylor HA Jr, Mickel MC, Chaitman BR, et al.: Long-term survival of African Americans in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1997, 29: 358-364.
51. Qureshi AI, Suri MAK, Safdar K, et al.: Intracerebral hemorrhage in blacks. Risk factors, subtypes, and outcome. Stroke 1997, 28: 961-964.
52. Hall WD, Ferrario CM, Moore MA, et al.: Hypertension-related morbidity and mortality in the southeastern United States. Am J Med Sci 1997, 313: 195-209.
53. Sacco RL, Roberts JK, Boden-Albala B, et al.: Race-ethnicity and determinants of carotid atherosclerosis in a multiethnic population. The Northern Manhattan Stroke Study. Stroke 1997, 28: 929-935.
54. Hypertension Detection and Follow-up Program Cooperative Group. Five year findings of Hypertension Detection and Follow-up Program II: Mortality by race-sex and age. JAMA 1979, 242: 2572-2576.
55. Bianchi S, Bigassi R, Baldari G, et al.: Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994, 7: 23-29.
56. Timio M, Venanzi S, Lolli S, et al.: "Non-dipper" hypertensive patients and progressive renal insufficiency: a 3-year longitudinal study. Clin Nephrol 1995, 43: 382-387.
57. Tomita H, Egashira K, Ohara Y, et al.: Early induction of transforming growth factor-B via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998, 32: 273-280.
58. Rumble JR, Gilbert RE, Cox A, et al.: Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy. J Hypertens 1998, 16: 1603-1609.
59. Peters H, Border WA, Noble NA: Targeting TGF-beta overexpression in renal disease: maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998, 54: 1570-1580.
60. Campistol JM, Inigo P, Jinenez W, et al.: Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999, 56: 714-719.
61. Sharma K, Eltayeb BO, McGowan TA, et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999, 34: 818-823.